Hyperglycemia impairs immune response; however, it remains unknown whether the anti-
tumor effects of anti-programmed cell death-1 antibody (PD-1-Ab) treatment are changed in hyperglycemic conditions. We analyzed the effect of PD-1-Ab on
tumor growth in
streptozotocin-induced diabetic mice (STZ-mice) subcutaneously inoculated with MC38 (a colon
carcinoma cell line). Furthermore, we assessed the expression of
chemokines by polymerase chain reaction (PCR) array in
tumor-draining lymph nodes (dLNs) of these mice and MC38 cells cultured in different
glucose concentrations. The suppressive effect of PD-1-Ab on
tumor growth was attenuated. This was accompanied by fewer
tumor-infiltrating CD8+ T cells, and STZ-mice had fewer
tumor-infiltrating CD11c+ dendritic cells (DCs) than normoglycemic mice.
mRNA expression levels of CXCL9, a
chemokine recruiting CD8+ T cells, were lower in dLNs of STZ-mice than in normoglycemic mice after PD-1-Ab treatment, and its
protein was expressed in DCs. In MC38 cells cultured with 25 mM
glucose,
mRNA expression of CCL7, a
chemokine recruiting DCs, was decreased compared to cells cultured with 5 mM
glucose. These results suggest that the STZ-induced
hyperglycemia impairs the effect of PD-1-Ab treatment on MC38
tumor growth, and is accompanied by reduced infiltration of DCs and CD8+ T cells and decreased expression of CCL7 and CXCL9.